PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wjgLink to Publisher's site
 
World J Gastroenterol. 2009 December 14; 15(46): 5864–5866.
Published online 2009 December 14. doi:  10.3748/wjg.15.5864
PMCID: PMC2791283

Is iron overload in alcohol-related cirrhosis mediated by hepcidin?

Abstract

In this case report we describe the relationship between ferritin levels and hepcidin in a patient with alcohol-related spur cell anemia who underwent liver transplantation. We demonstrate a reciprocal relationship between serum or urinary hepcidin and serum ferritin, which indicates that inadequate hepcidin production by the diseased liver is associated with elevated serum ferritin. The ferritin level falls with increasing hepcidin production after transplantation. Neither inflammatory indices (IL6) nor erythropoietin appear to be related to hepcidin expression in this case. We suggest that inappropriately low hepcidin production by the cirrhotic liver may contribute substantially to elevated tissue iron stores in cirrhosis and speculate that hepcidin replacement in these patients may be of therapeutic benefit in the future.

Keywords: Alcohol, Iron, Anaemia, Hepcidin, Cirrhosis

INTRODUCTION

Hepatic iron overload in alcohol related cirrhosis and the detrimental effect of excessive iron on hepatic tissues in this condition is well described[1]. Previous studies investigating whole-body retention of iron showed a two-fold increase in intestinal iron absorption in chronic alcoholism, and the underlying mechanism has not been identified[2].

Hepcidin, a 25 amino acid peptide, is the recently described body iron storage regulator. Under physiological conditions, hepcidin expression is stimulated by stored tissue iron, inflammatory stimuli and repressed by anemia and tissue hypoxia[3]. Recently, interactions between various signals affecting hepcidin production by hepatocytes have been elucidated[4]. Hepcidin binds to the iron exporter protein ferroportin on the basolateral aspect of macrophages and enterocytes and causes internalization and degradation of this molecule[5], rendering cells iron-loaded. The two major systemic effects of elevated hepcidin production are therefore reduction of intestinal iron uptake and reticulo-endothelial sequestration of iron.

As the erythron is the main user of iron, its requirement for red cell production is paramount. In the presence of anemia due to ineffective erythropoiesis, animal experiments have shown that an unidentified signal from bone marrow seems able to override the stimulus of elevated body iron stores, repressing hepcidin and allowing duodenal iron absorption to continue even in the presence of elevated iron stores[6].

Spur cell anemia (SCA) is an interesting clinical condition in which both erythropoiesis and tissue iron stores are altered by excessive alcohol consumption such that sufferers develop severe tissue iron overload and ongoing hemolysis[7]. The hemolysis is due to structural abnormalities of red cell membranes, resulting in spiculated erythrocytes (acanthocytes) which undergo early splenic destruction[8]. Treatment of SCA has been disappointing and it is commonly viewed as an indicator of end-stage liver disease[9].

We postulate that reduced hepcidin production in the cirrhotic liver might be a significant factor contributing to the body iron excess in this patient with end stage alcohol-induced cirrhosis and SCA who underwent orthotopic liver transplantation (OLT).

CASE REPORT

The patient was a 55-year old female with a 10-year history of excessive alcohol consumption who, following hospitalization due to decompensation and alcoholic hepatitis, became abstinent in May 2005. She remained stable until March 2006 when she developed worsening jaundice. Hematological findings indicated that hemolysis was a significant contributory factor in the patient’s jaundice. Subsequent investigations confirmed the diagnosis of SCA in the context of cirrhosis. She was referred for transplantion assessment in November 2006. She had an unconjugated hyperbilirubinaemia (230 U/L) and raised reticulocyte count (125 × 109/L). Hepatic synthetic function was relatively preserved with an INR of 1.5 and serum albumin concentration of 38 g/L. A blood film showed many acanthocytes with polychromasia and spherocytes. A transjugular liver biopsy showed micronodular cirrhosis and grade 1 siderosis. Her serum ferritin level at this time was greatly elevated at 600 ng/mL.

The patient decompensated further and was listed for transplantation. The blood film immediately before transplantation showed a predominance of acanthocytes (70%-80% of total red blood cells (RBC), and there was a gradual reduction in acanthocytes over the 48 h following transplantation so that examination of a blood film at 48 h after surgery indicated that acanthocytes made up 50%-60% of total circulating RBCs.

The patient gave consent for blood and urine samples collection for the study (LREC 08/MRE09/2). Samples were taken immediately before and at 12, 36, 48 h and 2 mo after transplantation. Blood was analyzed for ferritin, hemoglobin, erythropoietin, IL-6 and CRP to assess the extent of hemolysis and inflammation. Hepcidin was measured by SELDI-TOF using Cu2+ loaded IMAC ProteinChip Arrays and stable isotope labeled hepcidin as an internal standard as previously described[10] and available via http://www.hepcidin.bham.ac.uk/. Urine samples were normalized with respect to protein concentration (20 μg/mL, Bradford assay).

A sample of the explant liver was analyzed for hepcidin mRNA by q-RTPCR and this was compared with samples taken from 8 normal livers.

The hepcidin level in relation to hematological parameters is shown in Table Table1.1. Hepcidin levels before transplantation were very low compared with the elevated ferritin. Following transplantation, hepcidin production rose with falling ferritin. At 2 mo after transplantation, the hepcidin production had fallen in the context of the normal serum ferritin. The urinary hepcidin/ferritin ratio rose progressively following transplantation.

Table 1
Urinary hepcidin levels in relation to haemoglobin and ferritin

Figure Figure11 shows that the rise and subsequent fall in urinary hepcidin following transplantation does not seem to be related to erythropoietin production which remains quite stable (except for one dip at 12 h coincident with a two unit peri-operative blood transfusion). Similarly, IL6 levels did not vary greatly. CRP rose as expected in relation to the operation. This rise was not immediately accompanied with the dramatic rise in hepcidin production which was delayed for 12 h. Figure Figure22 illustrates a close correlation between urinary and serum hepcidin levels in this patient (Pearson correlation coefficient r = 0.958).

Figure 1
Variation in iron parameters with time.
Figure 2
Correlation between urinary and serum ferritin.

We compared hepcidin mRNA expression in the explant liver with that in 8 normal livers from transplant donor tissues. Hepcidin mRNA expression in the explant liver from our patient was significantly lower than that in normal liver (data not shown).

DISCUSSION

This case illustrates “inappropriate” low hepcidin production in an iron-over loaded cirrhotic patient with alcohol-related SCA. Following successful transplantation, hepcidin production by the new liver increased accompanied with falling serum ferritin. “Appropriate” hepcidin production by the new liver would act to sequester iron in reticulo-endothelial stores and to repress duodenal iron uptake. At 2 mo after OLT, both hepcidin and ferritin fell to low levels.

One potential mechanism for pre-operative hepcidin repression would be high circulating erythropoietin level in the hemolyzing patient. Apart from a small reduction in EPO in the peri-operative period which co-incided with a blood transfusion, EPO remained relatively high in the post-operative period consistent with observed persistence of spur cells and the ongoing anemia. This hepcidin expression in the new liver increased progressively. It is likely that hepcidin production in the new liver during the early post-transplantion period remains somewhat muted in relation to the ongoing EPO stimulus.

IL6 stimulates hepcidin production acutely through the STAT pathway. In our patient IL6 was low before transplantation and did not rise in the peri-operative period. CRP did rise in the immediate post-transplantation period as expected. This may have had a bearing on the observed increase in hepcidin as inflammation is a major trigger to hepcidin production.

In our case, although the cirrhosis was undoubtedly alcohol-related, the patient had been abstinent for 2 years. This raises the possibility that, even in the absence of an ongoing stimulus, a persistent hepatic oxidative state, perhaps induced by iron overload, could trigger ongoing repression of hepcidin production. This illustrates potentially differential effects of acute stimulation of hepcidin perhaps via the IL6/STAT pathway and chronic repression mediated by oxidative stress[11].

In summary, the cirrhotic liver in this patient with alcohol-induced spur cell anemia produced very little hepcidin in relation to circulating high ferritin levels and this deficiency was corrected by transplantation.

The mechanisms underlying reduced hepcidin production in this situation, in particular the role of oxidative stress as mediated through CHOP/CEBP, deserve further studies in the setting of human alcohol-related cirrhosis. The influence of alcoholic cirrhosis on duodenal expression of iron transporter proteins and the influence of local effects related to oxidative stress and external factors such as erythropoiesis on human hepcidin production clearly deserve further prospective examinations.

Footnotes

Supported by University Hospital Birmingham NHS Foundation Trust

Peer reviewer: Stefano Bellentani, Professor, Fondo Studio Malattie Fegato-ONLUS, Sezione di Campogalliano, Via R. Luxemburg, 29/N, 41011 Campogalliano, Italy

S- Editor Tian L L- Editor Ma JY E- Editor Ma WH

References

1. Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol. 2006;23:149–160. [PubMed]
2. Duane P, Raja KB, Simpson RJ, Peters TJ. Intestinal iron absorption in chronic alcoholics. Alcohol Alcohol. 1992;27:539–544. [PubMed]
3. Andrews NC. Forging a field: the golden age of iron biology. Blood. 2008;112:219–230. [PubMed]
4. De Domenico I, Ward DM, Kaplan J. Hepcidin regulation: ironing out the details. J Clin Invest. 2007;117:1755–1758. [PMC free article] [PubMed]
5. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093. [PubMed]
6. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108:3730–3735. [PubMed]
7. Chapman RW, Morgan MY, Laulicht M, Hoffbrand AV, Sherlock S. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig Dis Sci. 1982;27:909–916. [PubMed]
8. Takashimizu S, Shiraishi K, Watanabe N, Numata M, Kawazoe K, Miyachi H, Tokunaga M, Akatuka A, Matsuzaki S. Scanning electron microscopic studies on morphological abnormalities of erythrocytes in alcoholic liver diseases. Alcohol Clin Exp Res. 2000;24:81S–86S. [PubMed]
9. Chitale AA, Sterling RK, Post AB, Silver BJ, Mulligan DC, Schulak JA. Resolution of spur cell anemia with liver transplantation: a case report and review of the literature. Transplantation. 1998;65:993–995. [PubMed]
10. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem. 2007;53:620–628. [PubMed]
11. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008;134:226–238. [PubMed]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc